age 1 of 86
BCMAS FINAL EXAM STUDY GUIDE 2025/2026
ACCURATE QUESTIONS AND CORRECT DETAILED
ANSWERS WITH RATIONALES || 100% GUARANTEED
PASS <RECENT VERSION>
What is a study's perspective? .......Answer.........It describes the
types of costs relevant to the study's purpose with respect to
perspectives of the institution and payer
Which of the following is true of medical writers?
.......Answer.........They develop and produce print or digital
documents focused on medicine and healthcare
They must have strong knowledge in accurately interpreting and
communication scientific information
,age 2 of 86
They should have an interest in science, as the role is constantly
evolving through scientific advancements.
Most commonly used study design: .......Answer.........parallel
Under what conditions can a pharma company provide financial
support for conferences and CME? .......Answer.........The
grants/contributions are separate from other company funds
The company has had no control over the selection of content,
faculty, or venue
Not required by ADR reporting: .......Answer.........careful selection
of clinical trial participants
Required:
-recognition of events
,age 3 of 86
-safety signals are identified against a background of events
-accurate reporting
Individual board members are known as:
.......Answer.........advisors
in vitro diagnostic test - example .......Answer.........microbiology
culture
in vitro versus in vivo .......Answer.........in vitro describes something
"in glass" such as a test tube or petri dish
in vivo is "within a living organism"
Fundamental requirement for ongoing risk evaluations of REMS:
.......Answer.........timely data collection
, age 4 of 86
Best practice and ethical standards for reporting research
published in medical journals .......Answer.........ICMJE
T/F: Elements to Assure Safe Use (ETASU) are required medical
interventions taken by HCPs prior to using the drug.
.......Answer.........True
Combination product applicant(s) .......Answer.........The company
that holds the application for the combination product as a
whole
T/F: Severe birth defects is not an FDA mandated REMS.
.......Answer.........False
Export challenge of a medical device company:
.......Answer.........Violation of intellectual property rights
BCMAS FINAL EXAM STUDY GUIDE 2025/2026
ACCURATE QUESTIONS AND CORRECT DETAILED
ANSWERS WITH RATIONALES || 100% GUARANTEED
PASS <RECENT VERSION>
What is a study's perspective? .......Answer.........It describes the
types of costs relevant to the study's purpose with respect to
perspectives of the institution and payer
Which of the following is true of medical writers?
.......Answer.........They develop and produce print or digital
documents focused on medicine and healthcare
They must have strong knowledge in accurately interpreting and
communication scientific information
,age 2 of 86
They should have an interest in science, as the role is constantly
evolving through scientific advancements.
Most commonly used study design: .......Answer.........parallel
Under what conditions can a pharma company provide financial
support for conferences and CME? .......Answer.........The
grants/contributions are separate from other company funds
The company has had no control over the selection of content,
faculty, or venue
Not required by ADR reporting: .......Answer.........careful selection
of clinical trial participants
Required:
-recognition of events
,age 3 of 86
-safety signals are identified against a background of events
-accurate reporting
Individual board members are known as:
.......Answer.........advisors
in vitro diagnostic test - example .......Answer.........microbiology
culture
in vitro versus in vivo .......Answer.........in vitro describes something
"in glass" such as a test tube or petri dish
in vivo is "within a living organism"
Fundamental requirement for ongoing risk evaluations of REMS:
.......Answer.........timely data collection
, age 4 of 86
Best practice and ethical standards for reporting research
published in medical journals .......Answer.........ICMJE
T/F: Elements to Assure Safe Use (ETASU) are required medical
interventions taken by HCPs prior to using the drug.
.......Answer.........True
Combination product applicant(s) .......Answer.........The company
that holds the application for the combination product as a
whole
T/F: Severe birth defects is not an FDA mandated REMS.
.......Answer.........False
Export challenge of a medical device company:
.......Answer.........Violation of intellectual property rights
